About ATYR1940 (Resolaris™)
ATYR1940 is based on a protein naturally secreted from muscle (Resokine) that may act to influence T-cell activation at the tissue level to promote healthier muscle. There is potential that ATYR1940 may translate into an innovative therapeutic for rare genetic myopathies with an immune component, including limb-girdle muscular dystrophy (LGMD), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne muscular dystrophy (DMD). We collected evidence that supports applicability of ATYR1940 as an example of adding back a protein that is insufficiently produced by the human body to potentially counteract disease.
Resolaris: 1st in Class Protein Therapeutic Candidate
Harnessing the Resokine Pathway
Safety and Tolerability Profile
ATYR1940 is a slightly truncated version of the full Resokine protein. As such, the early clinical safety and tolerability data has high utility for all our Resokine pathway based programs.
To date, 44 patients have received ATYR1940 across three 3-month clinical trials with two extension studies for a total drug exposure of 204 patient months. In those trials, ATYR1940 was well tolerated in all doses tested, across various age groups, and with long-term exposure. No serious adverse events were reported by the study investigators. A low incidence of adverse events was reported in these trials and all adverse events were mild-to-moderate in intensity. There were no observed signs of general immunosuppressive effects which is consistent with a homeostatic pathway working at the tissue level.
Please click here to learn more about our ongoing clinical programs.